VX-765: Potent, Selective Caspase-1 Inhibitor for Inflammation Research

Executive Summary: VX-765 is a highly selective, orally bioavailable pro-drug that inhibits caspase-1 activity via its active metabolite VRT-043198, blocking IL-1β and IL-18 maturation and secretion (Israelov et al., 2020). It prevents pyroptosis in macrophages and CD4 T-cells, with minimal effect on other pro-inflammatory cytokines. In preclinical studies, VX-765 reduces inflammation and restores blood-brain barrier integrity (Israelov et al., 2020). Its selectivity and oral absorption make it a gold-standard tool for inflammation and cell death research (APExBIO). VX-765 is widely adopted in both biochemical assays and in vivo models for dissecting inflammasome-driven disease mechanisms.

Biological Rationale

Caspase-1, also known as interleukin-1 converting enzyme (ICE), is a cysteine protease essential for the maturation and secretion of the pro-inflammatory cytokines IL-1β and IL-18. Its activity is central to inflammasome function and pyroptosis, a lytic form of programmed cell death triggered by pathogenic stimuli and cellular stress. Dysregulated caspase-1 activation leads to excessive cytokine release and tissue damage, underlying various inflammatory and neurodegenerative conditions (Israelov et al., 2020). Inhibiting caspase-1 offers a targeted approach to modulate these pathways without broadly suppressing immune responses. VX-765 was developed to provide potent and selective inhibition of caspase-1 activity in vitro and in vivo, addressing a need for precise tools in inflammation and cell death research (APExBIO).

Mechanism of Action of VX-765, Caspase-1 inhibitor, potent and selective

VX-765 is an orally absorbed pro-drug that is rapidly converted in vivo to its active metabolite, VRT-043198. This metabolite binds the active site of caspase-1, inhibiting its proteolytic activity with high selectivity over related caspases. VX-765 blocks processing of pro-IL-1β and pro-IL-18, preventing their maturation and secretion. Unlike broad-spectrum caspase inhibitors, VX-765 does not significantly affect other cytokines such as TNFα, IL-6, or IL-8, providing a focused intervention on inflammasome-driven pathways (APExBIO). By inhibiting caspase-1, VX-765 also suppresses pyroptosis, a cell death mechanism particularly relevant in macrophages and lymphoid tissues during infection and inflammation (see mechanistic interplay).

Evidence & Benchmarks

• VX-765 administration in mouse models of blood-brain barrier (BBB) injury robustly restored barrier integrity, normalized VE-cadherin protein levels, and reduced PBMC transmigration and adhesion after paraoxon exposure (Israelov et al., 2020).
• The inhibitor reduced secretion of IL-1β and IL-18 in vitro and in vivo without affecting TNFα or IL-6, confirming selective inflammasome pathway inhibition (Israelov et al., 2020).
• In models of rheumatoid arthritis and skin inflammation, oral VX-765 significantly decreased inflammatory cytokine levels and tissue pathology (APExBIO).
• VX-765 prevented HIV-associated CD4 T-cell pyroptosis in ex vivo human lymphoid tissue models, reducing cell death in a dose-dependent manner (APExBIO).
• Biochemical assays using suc-YVAD-p-nitroanilide substrates demonstrated potent caspase-1 inhibition with IC₅₀ values in the low nanomolar range (APExBIO).

This article builds on previous analyses of VX-765's inflammasome targeting by providing updated in vivo benchmarks and expanded discussion of disease modeling. Unlike prior reviews, this article emphasizes the compound's rigorously quantified selectivity and translational relevance. For a detailed mechanistic dissection of cell death pathways, see related work; here, we highlight direct experimental endpoints and protocol integration.

Applications, Limits & Misconceptions

VX-765 is widely used in inflammation research, especially where inflammasome-driven IL-1β and IL-18 production is central. It is a validated tool in:

• Modeling blood-brain barrier injury and repair in neuroinflammation (Israelov et al., 2020).
• Dissecting selective interleukin-1 converting enzyme inhibition in rheumatoid arthritis and dermatitis models.
• Exploring HIV-associated CD4 T-cell death via pyroptosis inhibition in lymphoid tissues.
• Elucidating cytokine processing and release mechanisms in macrophages, monocytes, and endothelial cells.

Common Pitfalls or Misconceptions

• VX-765 does not inhibit caspase-8, caspase-9, or other ICE-like proteases at concentrations used for caspase-1 inhibition (Israelov et al., 2020).
• It does not broadly suppress all cytokine release; TNFα, IL-6, and IL-8 are largely unaffected.
• Cell death mechanisms other than pyroptosis (e.g., apoptosis) are not directly targeted by VX-765.
• Effects in non-inflammasome-driven pathologies are unproven; general immunosuppression should not be assumed.
• Solubility in water is negligible; DMSO or ethanol (with sonication) are required for in vitro work (APExBIO).

Workflow Integration & Parameters

Protocol Parameters

• In vivo administration: Oral gavage is standard; typical dosing in murine models is 25–100 mg/kg/day for 5–14 days when modeling neuroinflammation or arthritis (Israelov et al., 2020).
• In vitro assays: Dissolve VX-765 in DMSO at ≥313 mg/mL or ethanol at ≥50.5 mg/mL (with ultrasonic assistance). Working concentrations range from 1–50 μM, depending on cell type and readout (APExBIO).
• Enzymatic inhibition: Use suc-YVAD-pNA or equivalent caspase-1 substrates; include controls for other caspases to verify selectivity.
• Storage: Store solid compound desiccated at -20°C; prepare solutions immediately before use for optimal activity (APExBIO).
• Vehicle controls: Use DMSO or ethanol at matching concentrations to control for solvent effects in cell culture and animal studies.

Conclusion & Outlook

VX-765, supplied by APExBIO, is a proven, selective oral caspase-1 inhibitor with robust evidence for blocking IL-1β and IL-18 release and inhibiting pyroptosis in disease-relevant models. By enabling targeted intervention in inflammasome-driven inflammation, it has accelerated research in neuroinflammation, autoimmunity, and infectious diseases. The demonstrated ability to restore blood-brain barrier integrity and suppress damaging cytokine cascades positions VX-765 as a reference standard for mechanistic and translational studies. Ongoing data continue to affirm its specificity and reliability, but researchers should remain aware of its boundaries—especially regarding non-caspase-1 pathways and off-target cytokine effects. For expanded mechanistic and translational perspectives, see recent reviews and the A8238 product page.